Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Ketogenic diet therapy for patients with acromegaly

Official title: Ketogenic Diet Therapy in Patients With Acromegaly

Run by Erasmus Medical Center · NCT06949891 · Data updated 2026-11-12

This study tests whether a ketogenic diet can help people with acromegaly lower their growth hormone levels and improve their quality of life compared to a Mediterranean diet.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorErasmus Medical Center
Academic / other
Locations1 site (Rotterdam)
StatusRecruiting
StartedJune 1, 2023
Main results expectedDecember 31, 2027
Study endsMay 1, 2028
Registry record updatedApril 29, 2025
Trial IDNCT06949891 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with diagnosed acromegaly and elevated IGF-I levels due to a pituitary tumor.

Probably not a fit

Patients who are pregnant, breastfeeding, or have undergone recent pituitary surgery or radiotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of a ketogenic diet compared to a Mediterranean diet in patients diagnosed with acromegaly due to a pituitary adenoma. Acromegaly is characterized by excessive growth hormone production, leading to various health complications. The trial aims to assess whether dietary interventions can help normalize growth hormone and IGF-1 levels, potentially improving patient outcomes. Participants will be monitored for changes in metabolic parameters and overall quality of life.

Why it matters

Potential benefit: If successful, this approach could provide a novel dietary management strategy to improve health outcomes for patients with acromegaly.

How similar studies have gone: While dietary interventions in acromegaly are less commonly explored, preliminary studies suggest potential benefits, indicating this approach may be novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female, 18 years or older
* Diagnosis of acromegaly based on elevated GH and/or IGF-I levels due to a pituitary tumor
* IGF-I levels above 80% upper limit of the normal range (xULN)) on a stable medication dose for at least 4 months
* Written informed consent

Exclusion Criteria:

* Pregnancy or breastfeeding
* Pegvisomant treatment
* Has undergone pituitary surgery or radiotherapy within 6 months prior to s study entry;
* It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;
* History or presence of epilepsy;
* Participation in a trail of an experimental drug or device within 30 days prior to screening;
* Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
* Screening HbA1c \> 6,5%;
* Use of antidiabetic medication other than Metformin

Where it's running

  • Erasmus Medical Center
    Rotterdam, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.